Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 6713 - 6720 of 12007 results
NY Federal Court Dismisses Case Against Subsidies for Nuclear Energy
August 31, 2017| Blog| Viewpoint
Ineligible Coach On The Field – Assessing Whether Restrictions Are Enforceable In Contracts
August 31, 2017| Blog| Viewpoint
Fall Health Care Preview
August 31, 2017| Blog| Viewpoint
Hospitals and Others Respond to "Red Tape Relief Project" Requests
August 30, 2017| Blog| Viewpoint
Community Health Center Fund: A Minibus Rider
August 30, 2017| Blog| Viewpoint
New Hurdles in Access to U.S. Immigration Benefits - UPDATE
August 30, 2017| Alert| Viewpoint
MA Department of Energy Resources Files Final Revised Regulations for Solar Massachusetts Renewable Target Program
August 29, 2017| Blog| Viewpoint
A Warning from the FTC to Fast-Growing Companies: The Uber Consent Order
August 29, 2017| Blog| Viewpoint
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|